NCT04481386View on ClinicalTrials.gov

A Phase I Study of Vitargus® in Vitrectomy

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions
Vitreo-retinal Surgery
Interventions
DEVICE

Vitargus, BFC-1401

A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.

Trial Locations (1)

2000

Sydney Retina Clinic and Day Surgery, Sydney

Sponsors
All Listed Sponsors
lead

BioFirst Corporation

INDUSTRY

NCT04481386 - A Phase I Study of Vitargus® in Vitrectomy | Biotech Hunter | Biotech Hunter